The new assay uses nasopharyngeal swab specimens to detect SARS-CoV-2

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Applied BioCode’s CoV-2 Flu Plus Assay.

The new multiplex molecular diagnostic BioCode CoV-2 Flu Plus Assay is designed to detect and differentiate between SARS-CoV-2, respiratory syncytial virus (RSV), as well as influenza A subtypes such as seasonal H1, 2009 H1N1, H3, Influenza B simultaneously.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is intended to aid physicians to evaluate the clinical signs and symptoms of patients with a respiratory infection.

The PCR-based test uses nasopharyngeal swab specimens to detect SARS-CoV-2, influenza A, influenza B and RSV.

The assay runs on the company’s BioCode MDx-3000 Molecular System, which allows clinical laboratories to provide up to 564 results a day.

It represents Applied BioCode’s third EUA authorisation for Covid-19 testing from the FDA.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Previously, the company’s BioCode SARS CoV-2 Assay received EUA and for pooling up to five samples for the same test.

Applied BioCode president Winston Ho said: “We have taken an important next step in strengthening our infectious disease menu by upgrading the BioCode SARS-CoV-2 test to a panel that now also includes influenza A, influenza B and RSV.

“Our BioCode CoV-2 Flu Plus Assay will not only increase laboratory and hospital efficiency but will also help physicians to make a more informed decision.”

The new diagnostic assay builds on the company’s existing portfolio of syndromic assays that include its stand-alone EUA authorized BioCode SARS-CoV-2 Assay, FDA 510(k) cleared BioCode Gastrointestinal Pathogen Panel, and FDA 510(k) cleared BioCode Respiratory Pathogen Panel.

In November, Meridian Bioscience secured EUA from the US FDA for its Revogene SARS-CoV-2 assay.

 

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact